Education and Training
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Biospecimen Collection
- procedure: Functional Magnetic Resonance Imaging
- other: Questionnaire Administration
Eligibility
Inclusion Criteria:
Women Diagnosed with breast cancer
- Female
- Age 18 or older
- Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre
and during cortisol sampling (based on PI's clinical judgement)
- Agree to taking saliva samples and having fMRI scan
- No contraindications to MRI imaging (like ferromagnetic metal in their body)
- Proficiency in English sufficient to complete questionnaires and follow instructions
during the fMRI assessments
- US Citizen or resident able to receive payment legally
- Documented stage 0-III breast cancer
- Unilateral breast tumors
Controls
- Female
- Age 18 or older
- Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre
and during cortisol sampling (based on PI's clinical judgement)
- Agree to having saliva samples and fMRI scan
- No contraindications to MRI imaging (like ferromagnetic metal in their body)
- Proficiency in English sufficient to complete questionnaires and follow instructions
during the fMRI assessments
- US Citizen or resident able to receive payment legally
Exclusion Criteria:
Women Diagnosed with breast cancer
- Other active cancers within the past 10 years other than squamous cell carcinoma of
the skin
- Pregnant
- Any significant neurologic disease, such as dementia, multi-infarct dementia,
Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy,
seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain
injury
- Hearing impaired
- Current untreated psychosis, or bipolar disorder, or substance/alcohol
abuse/dependence
- Current use of psychotropic (based on PI's clinical judgement) medication 5 or more
days a week
Controls
- Cancer diagnosis, current or past
- Pregnant
- Any significant neurologic disease, such as dementia, multi-infarct dementia,
Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy,
seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain
injury
- Hearing impaired
- Current untreated psychosis, or bipolar disorder, or substance/alcohol
abuse/dependence
- Current use of psychotropic (based on PI's clinical judgement) medication 5 or more
days a week
- Breast cancer diagnosis in 1 first degree relative or 2 or more second degree
relatives
- Ovarian cancer diagnosis in 1 first or second degree relative
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Bita Nouriani
650-723-8479
Not Recruiting